Basel, 04 May 2017 Save the date: Roche Analyst Event at ISTH 2017 Monday, 10 July 2017, 6:30pm CEST We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. During the briefing, Roche will discuss new... Read more
Basel, 28 April 2017 Invitation to Roche Analyst Event at ASCO 2017 Monday, 5 June 2017, 5:15pm CDT We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (2 – 6... Read more
FRANKLIN LAKES, N.J., Apr. 26, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications. BD’s patented stochastic labelling technology incorporating molecular indexes (known also as UMIs or molecular barcodes), enables the... Read more
Basel, 26 April 2017 New data at AAN reinforce clinical benefit of Roche’s OCREVUS™ (ocrelizumab) for relapsing and primary progressive multiple sclerosis OCREVUS rapidly suppressed signs of disease activity in relapsing MS (RMS) patients In patients with early RMS – recently diagnosed and without prior treatment – OCREVUS was superior to Rebif® (interferon beta-1a) in... Read more
Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more
Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more
Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more
Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more
Basel, 17 April 2017 Roche announces positive interim results for emicizumab in phase III study of children with haemophilia A Emicizumab prophylaxis reduced the number of bleeds in children with haemophilia A and inhibitors to factor VIII Results build upon data for emicizumab in adults and adolescents with haemophilia A and inhibitors to factor VIII... Read more
Basel, 10 April 2017 Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared... Read more